Antifungal Prophylaxis Utilization and the Associated Clinical Outcomes Among Pediatric Patients with Hematological Malignancies or Undergoing Hematopoietic Stem Cell Transplantation
Bushra Al Siyabi, Juhaina Salim Al-Maqbali, Dhanalekshmi Unnikrishnan Meenakshi, Yasir Wali, Laila Al Yazidi, Daniela Cilloni · 2024
Read Antifungal Prophylaxis Utilization and the Associated Clinical Outcomes Among Pediatric Patients with Hematological Malignancies or Undergoing Hematopoietic Stem Cell Transplantation by Bushra Al Siyabi, Juhaina Salim Al-Maqbali, Dhanalekshmi Unnikrishnan Meenakshi, Yasir Wali, Laila Al Yazidi, Daniela Cilloni (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11642336.txt.
Description
Al Siyabi and co-authors published this hospital study in twenty twenty-four on preventing fungal infections in sick children. Children treated for blood cancers or given stem cell transplants face a high risk of deep fungal infections. Such infections can be deadly, so many children get antifungal drugs in advance as protection. The team reviewed care at a university hospital in Oman over six years.
Records for two hundred twenty-two children were studied. Most received protective antifungal drugs, though doses and choices varied. Children without protection had far more infections that needed treatment, much longer hospital stays, and higher death rates within ninety days. The authors back routine protection but call for shared, child-specific rules and closer drug level checks.
Catalog record
| CREATOR | Bushra Al Siyabi, Juhaina Salim Al-Maqbali, Dhanalekshmi Unnikrishnan Meenakshi, Yasir Wali, Laila Al Yazidi, Daniela Cilloni |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |